Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents
Language English Country Switzerland Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
16224185
DOI
10.1159/000088957
PII: 88957
Knihovny.cz E-resources
- MeSH
- Humans MeSH
- Mucositis chemically induced diagnosis MeSH
- Neoplasms complications drug therapy MeSH
- Intestinal Diseases chemically induced diagnosis MeSH
- Permeability MeSH
- Antineoplastic Agents adverse effects MeSH
- Intestinal Mucosa drug effects immunology metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Antineoplastic Agents MeSH
The diagnosis and assessment of the severity of intestinal mucosal damage in cancer patients treated with cytotoxic drugs still rely on anamnestic data. There is cumulative evidence that measurement of intestinal permeability may represent a sensitive indicator of intestinal damage by cytotoxic agents. The intestinal permeability testing is based on differential permeability of tight junctions along the crypt-villus axis to nonmetabolized sugars. Cytotoxic drugs induce flattening of villi, leading to increased exposure of luminal contents to crypts and increased disaccharide absorption. An increased disaccharide/monosaccharide ratio and decreased xylose absorption have been described in patients treated with different cytotoxic drugs across a spectrum of malignant tumors that correlated with clinical manifestations, and were used to monitor the effect of therapeutic interventions.
References provided by Crossref.org
Neopterin as a biomarker of immune response in cancer patients
Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy
